Evidence map›Paper›PMID 38142463›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2024

FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1.

Xiyu Wu, Masaaki Iwatsuki, Masakazu Takaki, Takuro Saito, Tsutomu Hayashi, Masato Kondo, Yoshiharu Sakai, Naoto Gotohda, Eiji Tanaka, Toshirou Nishida and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. ElevatedJournal of thoracic disease · 2024
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Xiyu WuDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Masaaki IwatsukiDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan. maiwa217@kumamoto-u.ac.jp.ORCID 0000-0002-0886-4618
Masakazu TakakiDepartment of Rehabilitation, Hospitality Care Garden Seisei Rehabilitation Hospital, Kasuga, Japan.
Takuro SaitoDepartment of Gastroenterological Surgery, Osaka University, Suita, Japan.
Tsutomu HayashiGastric Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
Masato KondoDepartment of Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Yoshiharu SakaiDepartment of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Naoto GotohdaDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Tokyo, Japan.
Eiji TanakaDepartment of Surgery, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
Toshirou NishidaDepartment of Surgery, Japan Community Health-Care Organization Osaka Hospital, Osaka, Japan.
Hideo BabaDepartment of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Kumamoto University · JPJapanese Red Cross Kumamoto Hospital · JPKobe City Medical Center General Hospital · JPKyoto University · JPNational Cancer Center Hospital East · JPOsaka Hospital · JPThe University of Osaka · JPTokyo National Hospital · JP

Funding

Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research 20K07594JST SPRING JPMJSP2127
6 · The paper itself

Abstract

backgroundImatinib contributes to improving prognosis of high-risk or unresectable gastrointestinal stromal tumors (GISTs). As therapeutic efficacy is limited by imatinib resistance and toxicity, the exploration of predictive markers of imatinib therapeutic efficacy that enables patients to utilize more effective therapeutic strategies remains urgent.

methodsThe correlation between FBXW7 and imatinib resistance via FBXW7-MCL1 axis was evaluated in vitro and in vivo experiments. The significance of FBXW7 as a predictor of imatinib treatment efficacy was examined in 140 high-risk patients with GISTs.

resultsThe ability of FBXW7 to predict therapeutic efficacy of adjuvant imatinib in high-risk GIST patients was determined through 5-year recurrence-free survival (RFS) rates analysis and multivariate analysis. FBXW7 affects imatinib sensitivity by regulating apoptosis in GIST-T1 cells. FBXW7 targets MCL1 to regulate apoptosis. MCL1 involves in the regulation of imatinib sensitivity through inhibiting apoptosis in GIST-T1 cells. FBXW7 regulates imatinib sensitivity by down-regulating MCL1 to enhance imatinib-induced apoptosis in vitro. FBXW7 regulates imatinib sensitivity of GIST cells by targeting MCL1 to predict efficacy of imatinib treatment in vivo.

conclusionsFBXW7 regulates imatinib sensitivity by inhibiting MCL1 to enhance imatinib-induced apoptosis in GIST, and predicts efficacy of imatinib treatment in high-risk GIST patients treated with imatinib.

Indexed as

Antineoplastic AgentsF-Box-WD Repeat-Containing Protein 7Gastrointestinal NeoplasmsGastrointestinal Stromal TumorsImatinib MesylateStomach NeoplasmsHumansMyeloid Cell Leukemia Sequence 1 ProteinAntineoplastic AgentsF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanImatinib MesylateMCL1 protein, humanMyeloid Cell Leukemia Sequence 1 ProteinApoptosisFBXW7Gastrointestinal Stromal TumorImatinibMCL1Resistance

Identifiers

PMID38142463
OpenAlexW4390167574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.